Stockpolly
Search
ABBV · NYSE · Drug Manufacturers - General

AbbVie

Develops immunology, neuroscience, oncology, and aesthetics products led by Skyrizi and Rinvoq.

$255.80
After-hours close+0.33 (+0.13%)
At close$255.47(−1.04%)
Loading prices…

Something off on this page? Send us feedback.

Profile

AbbVie Inc.ABBVHealth Care

Develops and sells medicines across immunology, neuroscience, oncology, and eye care, plus Botox Cosmetic and other aesthetics products. Skyrizi and Rinvoq now generate roughly half of revenue, making regulatory approvals, market access, and product exclusivity central to the business.

Develops, manufactures, and commercializes prescription medicines across immunology, neuroscience, oncology, and eye care, alongside Allergan Aesthetics products. Skyrizi and Rinvoq anchor immunology; Vraylar, Botox Therapeutic, Ubrelvy, and Qulipta serve neuroscience; Imbruvica, Venclexta, and Elahere cover blood and solid cancers; Botox Cosmetic and Juvederm lead aesthetics. Products are sold worldwide, with the United States generating most revenue.

Pairs internal research with licensing and acquisitions, then uses a global supply chain and commercial network to launch medicines and expand approved uses. Skyrizi and Rinvoq together produce roughly half of recent revenue as Humira declines after biosimilar entry. Sales depend on clinical and regulatory approvals, patent and regulatory exclusivity, payer reimbursement, and access through wholesalers, specialty pharmacies, and healthcare providers.

Company facts

CEORobert A. Michael
ListedJan 2, 2013
ExchangeNYSE
HeadquartersNorth Chicago, IL
CountryUnited States
Employees57,000
CIK0001551152
ISINUS00287Y1091

Categories

Key statistics

Market cap$451.38B
EPS (ttm)$3.55
P/E (ttm)71.98
ROE-136.5%
P/B−76.23
P/S7.01
Dividend yield2.67%
Beta−0.06vs XLV 1.12

Year to date +11.4% · Average volume (30d) 4.9M

Analysts

Price target, next 12 months$296.00+15.9%Median of 42 analysts · vs the Aug 28 close
ConsensusBuy30 of 42 analysts rate it buy or better

Ratings

Target range

Latest analyst notes

DateFirmActionPrior ratingRatingPrior targetTarget
Aug 20, 2026Piper SandlerReiterateOverweight$298$303
Aug 17, 2026Wells FargoReiterateOverweight$295$300
Aug 13, 2026Wolfe ResearchUpgradePeer PerformOutperform$127$300
Aug 4, 2026GuggenheimReiterateBuy$261$288
Aug 3, 2026Morgan StanleyReiterateOverweight$278$296

Earnings

EPS

Estimate$3.86
ReportedDue Oct 30, 2026

Revenue

Estimate$17.31B
ReportedDue Oct 30, 2026

History

Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseNext session
Jul 31, 2026Q2 FY26$3.61$3.65+1.1%$16.80B$16.99B+1.1%−2.51%
Apr 29, 2026Q1 FY26$2.59$2.65+2.3%$14.72B$15.00B+1.9%+3.64%
Feb 4, 2026Q4 FY25$2.65$2.71+2.3%$16.41B$16.62B+1.2%+0.88%
Oct 31, 2025Q3 FY25$1.77$1.86+5.1%$15.59B$15.78B+1.2%−2.79%
View details

Financial highlights

12 quartersQ1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
Revenue$13.34B$15.42B$15.78B$16.62B$15.00B$16.99B
Gross profit$9.34B$11.08B$10.47B$12.07B$10.78B$12.70B
Operating income$3.73B$4.89B$1.90B$5.81B$4.73B$6.43B
Net income$1.29B$938.0M$186.0M$1.82B$699.0M$3.61B
Diluted EPS$0.72$0.53$0.10$1.02$0.39$2.04
Gross margin70.0%71.8%66.4%72.6%71.9%74.7%
Operating margin28.0%31.7%12.1%35.0%31.6%37.9%

Fiscal years (4-quarter sums)FY21 $56.20B · FY22 $58.05B · FY23 $54.32B · FY24 $56.33B · FY25 $61.16B

Revenue by product · Q2 FY26

Skyrizi$5.51B · 36%
Rinvoq$2.53B · 17%
Other Products$1.11B · 7%
Vraylar$1.07B · 7%
Botox Therapeutic$1.04B · 7%
Venclexta$771.0M · 5%
H U M I R a$756.0M · 5%
Botox Cosmetic$728.0M · 5%
Imbruvica$532.0M · 4%
Ubrelvy$392.0M · 3%
Qulipta$350.0M · 2%
Other Aesthetics$309.0M · 2%

Revenue by geography · Q2 FY26

United States$4.77B · 86%
Non-US$760.0M · 14%

Balance sheet, Jun 30, 2026Cash & short-term investments $6.57B · Total debt $70.82B · Total assets $135.13B · Shareholders' equity −$5.94B

Dividends

Next ex-date
Oct 15, 2026
estimated · in 47 days
Annual dividend
$6.83
per share
Dividend yield
2.67%
Schedule
Quarterly
4 payments a year

Raised for 12 straight years — most recently to $1.73 from $1.64 in Jan 2026. To collect a payout, hold shares through the close before the ex-date.

History

Ex-dateRecordPaidAmountNote
Jul 15, 2026Jul 15Aug 14$1.73
Apr 15, 2026Apr 15May 15$1.73
Jan 16, 2026Jan 16Feb 17$1.73raised from $1.64
Oct 15, 2025Oct 15Nov 14$1.64
Jul 15, 2025Jul 15Aug 15$1.64
Apr 15, 2025Apr 15May 15$1.64
Jan 15, 2025Jan 15Feb 14$1.64raised from $1.55
Oct 15, 2024Oct 15Nov 15$1.55
View details

Ownership

Institutions 114.51%Insiders 0.08%

A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.

Shares outstanding 1.77B · Float 1.76B · 99.8% free float

Top shareholders13F · 13D/G · Form 4

HolderShares% outstandingFormFiled
BlackRock, Inc.149.49M8.46%13FAug 7, 2026
Vanguard Capital Management LLC115.40M6.53%13FAug 13, 2026
State Street Corp82.60M4.67%13FAug 7, 2026
Vanguard Portfolio Management LLC48.48M2.74%13FAug 13, 2026
JPMorgan Chase & Co47.86M2.71%13FAug 12, 2026

Insider tradesForm 4

DateInsiderRoleSharesAvg price
Aug 14, 2026Nicholas Donoghoeofficer: EVP, CHIEF BUS/STRAT OFFICER−32,710$250.00
Mar 4, 2026David Ryan Purdueofficer: SVP, Controller−5,230$233.56
Mar 2, 2026Perry C. Siatisofficer: EVP, GC AND SECRETARY−18,668$234.39
Feb 25, 2026Perry C. Siatisofficer: EVP, GC AND SECRETARY−22,381$230.00
View details

Peers

  • Sanofi (ADR)

    Dupixent is the world's #1 immunology drug and Skyrizi / Rinvoq's primary rival.

  • Johnson & Johnson

    Widest immunology-oncology overlap across every AbbVie growth franchise.

  • AstraZeneca (ADR)

    Calquence takes CLL share from Imbruvica with a cleaner cardiac safety profile.

  • Novartis (ADR)

    Cosentyx contests Skyrizi in psoriasis and PsA via IL-17A vs IL-23.

  • Merck

    Keytruda's .5B oncology scale overlaps AbbVie's hematology assets.

  • Eli Lilly

    Olumiant vs Rinvoq in JAK; Emgality rivals Botox Therapeutic in migraine.

CompareAfter-hours close

CompanyPriceChange
AbbVie$255.80+0.13%$451.38B72.016.87.0+10.2%
Sanofi (ADR)$44.83+0.02%$107.62B78.9—1.9+11.2%
Johnson & Johnson$268.40+0.13%$645.95B31.122.46.6+6.6%
AstraZeneca (ADR)$161.79−0.55%$252.33B24.415.24.1+6.4%
Novartis (ADR)$153.810.00%$292.35B23.216.45.3+0.9%
Merck$148.19−0.08%$366.18B118.717.25.5+5.1%
Eli Lilly$1,173.00−0.08%$1.10T39.428.713.9+47.7%
Median35.217.25.4+6.5%